May 1 |
G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook
|
May 1 |
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
|
May 1 |
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
|
Apr 30 |
G1 Therapeutics Q1 2024 Earnings Preview
|
Apr 19 |
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit
|
Apr 17 |
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
|
Apr 12 |
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
|
Apr 4 |
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 22 |
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
|
Feb 29 |
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
|